Cisplatin-loaded thermoresponsive liposomes for enhanced anticancer efficacy

Shah, Hassan; Madni, Asadullah; Filipczak, Nina; Jan, Nasrullah; Khan, Muhammad Muzammil; Khan, Safiullah; Basit, Abdul; Shafiq, Afifa; Rai, Nadia; Yalamarty, Satya Siva Kishan; Torchilin, Vladimir P.

doi:10.1016/j.jddst.2023.104509

Cited by 8 publications

(2 citation statements)

References 42 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Thermoresponsive liposomes were investigated in a research to improve their anti-cancer effectiveness (Shah et al, 2023).…”

Section: Drug Releasementioning

confidence: 99%

Cancer signaling, cell/gene therapy, diagnosis and role of nanobiomaterials

Rosic

2024

ABES

View full text Add to dashboard Cite

An important characteristic of cancer is aberrant metabolism. Drug resistance, cancer stem cells, metastasis and tumorigenesis are all significantly impacted by abnormal cancer metabolism, which includes enhanced anabolic pathways and aerobic glycolysis. The Hippo pathway, Myc and PI3K/AKT are recognized oncogenic signaling networks that control the expression of metabolic genes and increase the level of activity of metabolic enzymes. On the other hand, abnormal metabolic pathways result in disruptions to the internal signal transduction pathways of cells, providing energy, building blocks and redox capabilities necessary for uncontrolled cancer cell proliferation. Studies and clinical trials are being carried out to investigate the impact of minute substances or dietary modifications, such as calorie restriction, fasting and intermittent fasting, on the inhibition of metabolic enzymes. The metabolic phenotypes of malignancies are remarkably diverse, much like genetic variability. Genetic abnormalities and a variety of signals found in the tumor microenvironment contribute to this variability. Therefore, one of the main objectives of contemporary cancer therapies is to overcome metabolic plasticity. This overview explains the relationships between biochemical and pathways of signaling and emphasizes recent research on the metabolic properties of cancer. We also present fresh justifications for the upcoming class of medications that target cancer metabolism. This is an overview of our latest studies on the progress of nanomedicine and disease detection at the tiny level of nano-bio interactions between biological systems and nanoparticles. Significant progress in the field of nanomedicine has been accomplished in the last 20 years. However, the absence of a thorough knowledge of nano-bio interactions in the clinical situation makes it difficult to significantly improve overall patient survival with nanomedicine.

show abstract

“…Thermoresponsive liposomes were investigated in a research to improve their anti-cancer effectiveness (Shah et al, 2023).…”

Section: Drug Releasementioning

confidence: 99%

Cancer signaling, cell/gene therapy, diagnosis and role of nanobiomaterials

Rosic

2024

ABES

View full text Add to dashboard Cite

show abstract

“…These nanoreactors remain inactive in normal tissues but are activated by the acidic TME, triggering the release of reactive species to induce oxidative stress and suppress the antioxidant abilities of cancer cells, thus leading to synergistic tumor ablation [ 45 ]. A study [ 46 ] worked on thermoresponsive liposomes for enhanced anti-cancer efficacy. They observed the more significant cytotoxicity of cisplatin-loaded thermoresponsive liposomes at higher temperatures, aligning with the elevated temperature at tumor sites.…”

Section: Nanoparticle-mediated Drug Deliverymentioning

confidence: 99%

Cancer Nanomedicine: Emerging Strategies and Therapeutic Potentials

Han

Xiong

et al. 2023

Molecules

View full text Add to dashboard Cite

Cancer continues to pose a severe threat to global health, making pursuing effective treatments more critical than ever. Traditional therapies, although pivotal in managing cancer, encounter considerable challenges, including drug resistance, poor drug solubility, and difficulties targeting tumors, specifically limiting their overall efficacy. Nanomedicine’s application in cancer therapy signals a new epoch, distinguished by the improvement of the specificity, efficacy, and tolerability of cancer treatments. This review explores the mechanisms and advantages of nanoparticle-mediated drug delivery, highlighting passive and active targeting strategies. Furthermore, it explores the transformative potential of nanomedicine in tumor therapeutics, delving into its applications across various treatment modalities, including surgery, chemotherapy, immunotherapy, radiotherapy, photodynamic and photothermal therapy, gene therapy, as well as tumor diagnosis and imaging. Meanwhile, the outlook of nanomedicine in tumor therapeutics is discussed, emphasizing the need for addressing toxicity concerns, improving drug delivery strategies, enhancing carrier stability and controlled release, simplifying nano-design, and exploring novel manufacturing technologies. Overall, integrating nanomedicine in cancer treatment holds immense potential for revolutionizing cancer therapeutics and improving patient outcomes.

show abstract